Status:
UNKNOWN
Evaluation of the Effects of KCNQ1 Mutation on Insulin Tolerance and Obsessive Compulsive Features in Long QT Romano-Ward Syndrome Patients.
Lead Sponsor:
Biotrial
Collaborating Sponsors:
European Union
Nantes University Hospital
Conditions:
Romano-Ward Syndrome
Long QT Syndrome
Eligibility:
All Genders
18-48 years
Phase:
NA
Brief Summary
The objectives of the study are to investigate if KCNQ1 mutation in Romano-Ward long QT patients can be associated with changes in insulin regulation and with psychological features of compulsivity, i...
Detailed Description
Romano-Ward Syndrome (RWS) is a rare disorder characterized by prolongation of the QT interval, as well as T-wave abnormalities and possibly polymorphic ventricular fibrillation. RWS is inherited in a...
Eligibility Criteria
Inclusion
- In the investigator's opinion, the subject is generally healthy based on their medical records (subjects with KCNQ1 mutation only), medical history, physical examination, vital signs, body weight, ECG (except long QT if applicable), and based on the results of haematology, clinical chemistry, urinalysis, urine drug screen (UDS) and serology;
- Subjects with a KCNQ1 mutation: genotyped as having a mutation on the KCNQ1 gene with or without phenotypic manifestation of long QT syndrome;
- Relatives of subjects with a KCNQ1 mutation: KCNQ1-mutated family relatives (with or without phenotypic expression) of a subject carrying a KCNQ1 mutation (Romano-Ward patients or subjects without phenotypic manifestation of long QT syndrome);
- Relatives of subjects with a KCNQ1 mutation must live in a different household than the subject with the KCNQ1 mutation;
- All subjects: negative UDS by dipstick analysis: opiates, methadone, cocaine, amphetamines (including ecstasy), barbiturates, benzodiazepines, and cannabinoids at admission to the assessment visit;
- All subjects: negative alcohol breath test at admission to the assessment visit.
Exclusion
- All subjects: having taken within 1 year before the assessment visit or currently taking any of the following medications: a. Antidiabetics: metformin, pioglitazone, acarbose, miglitol, sitagliptin, vildagliptin, saxagliptin, exenatide, liraglutide, semaglutide, repaglinide, nateglinide, insulin. b. Medications interfering with the central nervous system (CNS) such as any antipsychotic, antidepressant or regular use of anxiolytic medications \> once a week, or any attention deficit/hyperactivity disorder (ADHD) medication (e.g. methylphenidate);
- Healthy subjects and relatives of subjects with a KCNQ1 mutation not phenotypically affected: any of the following on a de novo ECG: a. Heart rate (HR) \< 40 bpm or \> 100 bpm; b. PR interval \<120 msec; c. Abnormal repolarization; d. QT interval corrected for HR using Fridericia's formula (QTcF) \> 450 msec for male subjects or \> 470 msec for female subjects.
Key Trial Info
Start Date :
January 8 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2021
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04715256
Start Date
January 8 2021
End Date
December 1 2021
Last Update
January 20 2021
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
L'Institut du Thorax, Nantes Hospital
Nantes, France, 44000
2
Biotrial Clinical Unit
Rennes, France, 35000